BillionToOne, Inc. (BLLN) shares fell 4.54% to $89.65 after the company announced new prenatal screening results. The study reported 94.4% sensitivity and 99.5% specificity for Unity Fetal Risk Screen in general-risk pregnancies. The clinical findings add support for broader use of cfDNA fetal risk assessment.

BillionToOne stock remained under pressure during Tuesday's session despite the update. Shares traded near $89.65 after falling from about $94 earlier in the session, reflecting a clear intraday decline. At the same time, the study adds new clinical evidence as BillionToOne expands its prenatal testing portfolio and market reach. cfDNA-based screening is already a routine part of prenatal care for assessing fetal chromosomal conditions, and extending the method to monogenic fetal risk assessment is a newer application of the same underlying technology.

Prospective study tests routine prenatal screening

The prospective study included 2,212 pregnant carriers across nine U.S. institutions with unknown partner carrier status. Researchers assessed fetal risk for cystic fibrosis, spinal muscular atrophy, and alpha- and beta-hemoglobinopathies. Outcome data covered 98.6% of pregnancies completing care at participating sites, supporting a broad assessment.

The study focused on general-risk pregnancies rather than groups selected for known risks or other medical indications. That approach gives BillionToOne a clinical development narrative tied to routine prenatal care. The prospective design also reflects how clinicians can use cfDNA testing as a primary screen during ordinary prenatal care. U.S. obstetric guidance already calls for offering carrier screening for conditions such as cystic fibrosis and spinal muscular atrophy during pregnancy, so the evaluated conditions sit within established screening practice.

Unity reports strong screening performance

Unity Fetal Risk Screen recorded 94.4% sensitivity, meaning the test identified most affected pregnancies in the study. The assay also reached 99.5% specificity and more than 99.9% negative predictive value across the evaluated conditions. The test provides quantitative fetal risk estimates, ranging from 9-in-10 risk to as low as 1-in-10,000.

Traditional carrier screening can require partner testing, but follow-up may face financial, logistical, or access barriers. cfDNA testing can assess fetal risk directly instead of relying only on parental genotype results. A direct fetal risk estimate also carries a practical benefit: most pregnancies can be reassured without invasive diagnostic procedures such as amniocentesis or chorionic villus sampling, which carry a small procedural risk, while positive screening results still require confirmatory diagnostic testing. For conditions such as spinal muscular atrophy, where presymptomatic treatment has been associated with improved outcomes, earlier fetal risk information can support timelier clinical planning. BillionToOne now has new clinical evidence supporting its prenatal screening strategy.

BillionToOne expands its prenatal testing platform

Unity Fetal Risk Screen is part of BillionToOne's Unity Complete prenatal screening portfolio. The company uses its Quantitative Counting Template technology to support its testing approach. BillionToOne recently expanded its fetal risk screen portfolio with a new 130-gene panel.

The expansion gives BillionToOne another clinical milestone as the company broadens its screening offering. The latest study also adds evidence from routine-care settings. Noninvasive prenatal testing is an established global market built around chromosomal screening, and quantitative monogenic fetal risk assessment is the segment where Unity is positioned. For BillionToOne, the clinical update arrives as shares remain under intraday pressure.

Overall, the study provides additional clinical evidence for BillionToOne's prenatal testing platform and accessibility goals. The company positions the portfolio around earlier detection and broader access to prenatal genetic information. As with earlier prenatal screening tools, wider adoption of primary cfDNA fetal risk assessment typically depends on peer-reviewed evidence, inclusion in clinical guidelines, and payer coverage decisions. The latest results support that strategy as clinical adoption continues to develop.

The post BillionToOne, Inc. (BLLN) stock: New Study Shows 94.4% Sensitivity in Prenatal Genetic Screening appeared first on Blockonomi.